Balversa

Chemical Nameerdafitinib
Dosage FormTablet (oral; 3 mg, 4 mg, 5 mg)
Drug ClassKinase inhibitors
SystemUrinary
CompanyJanssen Biotech
Approval Year2019

Indication

  • Balversa is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Balversa (erdafitinib) Prescribing Information2019Janssen Biotech
Document TitleYearSource
Erdafitinib in locally advanced or metastatic urothelial carcinoma.2019New England Journal of Medicine